Harvard Bioscience (HBIO) Gross Margin (2010 - 2026)

Harvard Bioscience (HBIO) has reported Gross Margin for 17 consecutive years, with 55.57% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Margin fell 82.0% year-over-year to 55.57% in Q2 2026; TTM through Jun 2026 was 58.16%, a 126.0% increase from a year earlier, with the FY2025 full-year figure at 57.67%, down 51.0% from the prior year.
• Gross Margin was 55.57% for Q2 2026 at Harvard Bioscience, down from 58.99% in the prior quarter.
• Over five years, Gross Margin peaked at 61.2% in Q1 2023 and troughed at 45.21% in Q3 2022.
• A 5-year average of 57.05% and a median of 57.6% in 2023 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin plunged 977 bps in 2022 and surged 1285 bps in 2023, its largest moves.
• Over 5 years, Gross Margin stood at 55.7% in 2022, then rose by 4 bps to 57.99% in 2023, then slipped by 2 bps to 57.06% in 2024, then grew by 5 bps to 59.71% in 2025, then declined by 7 bps to 55.57% in 2026.
• The last three Gross Margin figures came in at 55.57% (Q2 2026), 58.99% (Q1 2026), and 59.71% (Q4 2025), per Business Quant data.